|
| Status |
Public on Dec 28, 2020 |
| Title |
Gene expression analyses of palbociclib treated ER+ breast cancer cell lines as assessed by RNA-seq |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The goal of this study is to measure gene expression changes resulting over time of palbociclib treatment of T47D, MCF7, and CAMA1 ER+ breast cancer cell lines.
|
| |
|
| Overall design |
Examination of gene expression changes in ER+ breast cancer cell lines (T47D, MCF7 and CAMA1) treated with palbociclib for 2, 7, 10 and 14 days. As a control, each of the three cell lines has vehicle treated sub-confluent log phase growing cells for comparison with palbociclib treated cells.
|
| |
|
| Contributor(s) |
Mazurek A, Zhong W, Maskey R |
| Citation(s) |
33356791 |
| |
| Submission date |
Apr 07, 2020 |
| Last update date |
Jun 27, 2021 |
| Contact name |
Reeja Maskey |
| Organization name |
PFIZER INC.
|
| Department |
Oncology Research & Development
|
| Lab |
Integrative Biotechnology Group
|
| Street address |
401 N Middletown Rd
|
| City |
Pearl River |
| State/province |
NY |
| ZIP/Postal code |
10965 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (15)
|
|
| Relations |
| BioProject |
PRJNA623621 |
| SRA |
SRP255639 |
Less...
More...